27 results
DEFM14A
BCEL
Atreca Inc - Ordinary Shares
23 Feb 24
Proxy related to merger
5:21pm
, 2023, we entered into the Asset Purchase Agreement. Upon the terms and subject to the satisfaction or waiver of the conditions of the Asset Purchase … reserve, the amount to be paid in satisfaction of such contingencies, the achievement of both Milestones within the time period described in the CVR
8-K
EX-10.1
BCEL
Atreca Inc - Ordinary Shares
6 Feb 24
Departure of Directors or Certain Officers
4:00pm
”), then in full satisfaction of any obligation to provide you with severance benefits under your Executive Employment Agreement with the Company effective … further expressly acknowledge and agree that: (i) the benefits being provided to you under this Agreement are in full satisfaction of any severance
8-K
EX-10.2
BCEL
Atreca Inc - Ordinary Shares
6 Feb 24
Departure of Directors or Certain Officers
4:00pm
”), then in full satisfaction of any obligation to provide you with severance benefits under your Executive Employment Agreement with the Company effective … expressly acknowledge and agree that the benefits being provided to you under this Agreement are in full satisfaction of any severance benefits you
PREM14A
BCEL
Atreca Inc - Ordinary Shares
5 Jan 24
Preliminary proxy related to merger
4:57pm
Purchase Agreement. Upon the terms and subject to the satisfaction or waiver of the conditions of the Asset Purchase Agreement, Immunome will acquire … to be paid in satisfaction of such contingencies, the achievement of both Milestones within the time period described in the CVR Agreement, the obligations
DEFA14A
EX-2.1
BCEL
Atreca Inc - Ordinary Shares
26 Dec 23
Additional proxy soliciting materials
8:39am
no later than two (2) Business Days after) the satisfaction of all conditions (other than those that by their terms are to be satisfied or taken … contemplated hereby or thereby to which Seller is a party. As of the Closing Date, Seller will pay or make adequate provision for the satisfaction
DEFA14A
duxqgkx 8u
26 Dec 23
Additional proxy soliciting materials
8:39am
DEFA14A
EX-10.1
x9qfl
26 Dec 23
Additional proxy soliciting materials
8:39am
8-K
9g9ky 8rceewbie4i
26 Dec 23
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
8:38am
8-K
EX-2.1
1ylk6qfw
26 Dec 23
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
8:38am
8-K
EX-10.1
nwi0eq9l
26 Dec 23
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
8:38am
8-K
EX-10.1
zpr8bg 7bld3aw84
21 Sep 23
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
8:01am